We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Perrigo (PRGO) Unit Files for OTC Birth Control Pill With FDA
Read MoreHide Full Article
Perrigo Company plc (PRGO - Free Report) announced that its wholly owned subsidiary, HRA Pharma, has submitted an application seeking approval for the first-ever over-the-counter (“OTC”) birth control pill, Opill, from the FDA.
Upon potential approval, Opill will become the first daily birth control pill made available OTC without a prescription in the United States. The company has applied for an Rx-to-OTC switch for Opill (also known as a mini pill or non-estrogen pill), a progestin-only daily birth control pill
Opill was approved by the FDA in 1973 and has been available in the United States as a prescription birth control pill for almost five decades.
Removing the requirement of a prescription for Opill would help American women get easy access to a contraceptive method that is more effective at preventing pregnancy compared to all current methods available OTC.
Shares of Perrigo have rallied 7.9% so far this year against the industry’s decline of 26.1%.
Image Source: Zacks Investment Research
The news, though not related directly, comes in the wake of the recent Roe v Wade overturning. Per a Wall Street Journal article, the U.S. Supreme Court has recently overturned the 1973 Roe v. Wade decision, following which abortion became mostly illegal in many U.S. states.
Owing to this, demand for birth control pills is likely to increase in the upcoming days as these are safe for most women to use.
Increasing easy access to an OTC birth control pill is likely to provide women with better control of their reproductive life without facing unnecessary barriers. Approval of non-prescription birth control pills has been advocated by health experts for some time. They feel these pills should be available easily over the counter.
The Zacks Consensus Estimate for Leap Therapeutics’ loss per share has narrowed 11.1% for 2022 and 5.9% for 2023 in the past 60 days.
Earnings of Leap Therapeutics have surpassed estimates in three of the trailing four quarters and missed the same on the other occasion. LPTX delivered an earnings surprise of 1.92%, on average.
Fate Therapeutics’ loss per share estimates narrowed 0.9% for 2022 and 0.5% for 2023 in the past 60 days.
Earnings of Fate Therapeutics have surpassed estimates in two of the trailing four quarters and missed the same on the other two occasions. FATE delivered an earnings surprise of -0.72%, on average.
Precision BioSciences’ loss per share estimates narrowed 18.1% for 2022 and 29.5% for 2023 in the past 60 days.
Earnings of Precision BioSciences have surpassed estimates in each of the trailing four quarters. DTIL delivered an earnings surprise of 76.15%, on average.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Perrigo (PRGO) Unit Files for OTC Birth Control Pill With FDA
Perrigo Company plc (PRGO - Free Report) announced that its wholly owned subsidiary, HRA Pharma, has submitted an application seeking approval for the first-ever over-the-counter (“OTC”) birth control pill, Opill, from the FDA.
Upon potential approval, Opill will become the first daily birth control pill made available OTC without a prescription in the United States. The company has applied for an Rx-to-OTC switch for Opill (also known as a mini pill or non-estrogen pill), a progestin-only daily birth control pill
Opill was approved by the FDA in 1973 and has been available in the United States as a prescription birth control pill for almost five decades.
Removing the requirement of a prescription for Opill would help American women get easy access to a contraceptive method that is more effective at preventing pregnancy compared to all current methods available OTC.
Shares of Perrigo have rallied 7.9% so far this year against the industry’s decline of 26.1%.
Image Source: Zacks Investment Research
The news, though not related directly, comes in the wake of the recent Roe v Wade overturning. Per a Wall Street Journal article, the U.S. Supreme Court has recently overturned the 1973 Roe v. Wade decision, following which abortion became mostly illegal in many U.S. states.
Owing to this, demand for birth control pills is likely to increase in the upcoming days as these are safe for most women to use.
Increasing easy access to an OTC birth control pill is likely to provide women with better control of their reproductive life without facing unnecessary barriers. Approval of non-prescription birth control pills has been advocated by health experts for some time. They feel these pills should be available easily over the counter.
Zacks Rank & Stocks to Consider
Perrigo currently carries a Zacks Rank #3 (Hold). Better-ranked stocks in the biotech sector are Leap Therapeutics, Inc. (LPTX - Free Report) , Fate Therapeutics, Inc. (FATE - Free Report) and Precision BioSciences, Inc. (DTIL - Free Report) , all carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Zacks Consensus Estimate for Leap Therapeutics’ loss per share has narrowed 11.1% for 2022 and 5.9% for 2023 in the past 60 days.
Earnings of Leap Therapeutics have surpassed estimates in three of the trailing four quarters and missed the same on the other occasion. LPTX delivered an earnings surprise of 1.92%, on average.
Fate Therapeutics’ loss per share estimates narrowed 0.9% for 2022 and 0.5% for 2023 in the past 60 days.
Earnings of Fate Therapeutics have surpassed estimates in two of the trailing four quarters and missed the same on the other two occasions. FATE delivered an earnings surprise of -0.72%, on average.
Precision BioSciences’ loss per share estimates narrowed 18.1% for 2022 and 29.5% for 2023 in the past 60 days.
Earnings of Precision BioSciences have surpassed estimates in each of the trailing four quarters. DTIL delivered an earnings surprise of 76.15%, on average.